ARS Pharmaceuticals Inc (NASDAQ:SPRY) price on Thursday, March 28, rose 2.61% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $10.22.
A look at the stock’s price movement, the close in the last trading session was $9.96. Turning to its 52-week performance, $10.20 and $2.55 were the 52-week high and 52-week low respectively. Overall, SPRY moved 13.30% over the past month.
ARS Pharmaceuticals Inc’s market cap currently stands at around $986.23 million. Analysts project the company’s earnings per share (EPS) to be -$0.11, which has seen fiscal year 2024 EPS growth forecast to increase to -$0.61 and about -$0.53 for fiscal year 2025. Per the data, EPS growth is expected to be -7.00% for 2024 and 13.10% for the next financial year.
Wall Street analysts have also projected the company’s year-on-year revenue for 2024 to grow to $5.34 million, representing a 17,700.00% jump on that reported in the last financial year.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was 1 upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that SPRY is a 100% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
SPRY’s current price about 14.77% and 32.16% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 69.52, while 7-day volatility ratio is 8.41% and 6.19% in the 30-day chart. Further, ARS Pharmaceuticals Inc (SPRY) has a beta value of 0.81, and an average true range (ATR) of 0.58.
If we refocus on ARS Pharmaceuticals Inc (NASDAQ:SPRY), historical trading data shows that trading volumes averaged 1.33 million over the past 10 days and 607.99K over the past 3 months. The company’s latest data on shares outstanding shows there are 96.41 million shares.
The 56.81% of ARS Pharmaceuticals Inc’s shares are in the hands of company insiders while institutional holders own 42.11% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 4.25 million on Mar 15, 2024, giving us a short ratio of 5.03. The data shows that as of Mar 15, 2024 short interest in ARS Pharmaceuticals Inc (SPRY) stood at 4.41% of shares outstanding, with shares short falling to 4.86 million registered in Feb 15, 2024. Current price change has pushed the stock 86.50% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the SPRY stock continues to rise going into the next quarter.
